Loading
A phase 2 trial of PM 8.4 mg/m^2 in diffuse large B-cell lymphoma, run by Chengdu Zenitar Biomedical Technology Co., Ltd, active and no longer recruiting.
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) is a phase 2 interventional study registered as NCT05563844 by Chengdu Zenitar Biomedical Technology Co., Ltd, with 74 participants enrolled, started 2022-11-08 and due to reach its primary completion in 2026-12-30. Interventions recorded: PM 8.4 mg/m^2 and PM 11.2 mg/m^2.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Diffuse large B-cell lymphoma and the tag pipeline.
Shares Diffuse large B-cell lymphoma and the tag pipeline.
Shares Diffuse large B-cell lymphoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/